Skip to main content
profile image
Selected Works of Shu-Ching Chang, PhD, MS
Article
Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).
Journal of Clinical Oncology (2020)
  • Katherine Sanchez, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Shu-Ching Chang, Medical Data Research Center, Portland, OR;
  • Isaac Kim, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Maritza Martel, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Yaping Wu, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • William L Redmond, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Zhaoyu Sun, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Dottie Waddell, Providence Health & Services
  • Deborah R. Laxague, Patient Advocate, Grenada, CA;
  • Brady Bernard, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Monil Shah, Brooklyn ImmunoTherapeutics, New York, NY;
  • Walter John Urba, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • David B. Page, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
Link
Disciplines
Publication Date
May 20, 2020
DOI
10.1200/JCO.2020.38.15_SUPPL.E12589
Citation Information
Katherine Sanchez, Shu-Ching Chang, Isaac Kim, Maritza Martel, et al.. "Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC)." Journal of Clinical Oncology Vol. 38 (2020)
Available at: http://works.bepress.com/shu-ching-chang/63/